Favipiravir

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

Retrieved on: 
Friday, August 18, 2023
Biotechnology, Other Health, Diabetes, Health, General Health, Medical Devices, Research, Infectious Diseases, Surgery, Science, Clinical Trials, Inc., GMP, DTC, Stiff-person syndrome, DNA, Allergy, Pharyngealization, Mayo Clinic, Central nervous system, Therapy, Life, Clinical trial, Genetics, STI, Marketing, Urinary tract infection, Genomics, Safety, COVID-19, Direct-to-consumer advertising, Point of care, Favipiravir, CTA, Infection, E-commerce, Autoimmunity, Psoriasis, Nature, RSV, Acquisition, Patient, Organ transplantation, Immune system, Medicine, Viral, Entrepreneurship, Clinical professor, Neurology, Skin, Social media, Software, Vaccine, Pharmaceutical industry, T1D

For Q2 2023 and the first half of the Q3 2023, we have been heavily focused on ongoing conversations around promising innovations.

Key Points: 
  • For Q2 2023 and the first half of the Q3 2023, we have been heavily focused on ongoing conversations around promising innovations.
  • We also mutually agreed to terminate the non-binding letter of intent with Natural State Genomics and Natural State Laboratories.
  • Since the founding of Aditxt, we have believed that commercializing health innovations deserves a new approach driven by stakeholders.
  • Continuing to expand product pipeline, research, and development, and have wider commercial reach with patients with a POC testing platform.

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Retrieved on: 
Tuesday, November 1, 2022
Annual report, Nobel Prize, CRO, Cocrystal, SEC, GLOBE, Nasdaq, Norovirus, COCP, Patent, CAGR, Private Securities Litigation Reform Act, Union, Patient, Severe acute respiratory syndrome coronavirus 2, Medicines and Healthcare products Regulatory Agency, Risk, Vaccine, Pharmaceutical industry, Favipiravir

Cocrystal recently announced the completion of enrollment in a Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A, with topline study results expected later this year.

Key Points: 
  • Cocrystal recently announced the completion of enrollment in a Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A, with topline study results expected later this year.
  • The granting of this patent is an important step in our efforts to expand protection of our novel, best-in-class antiviral candidates both in the U.S. and internationally.
  • CC-42344 is an oral PB2 inhibitor discovered using Cocrystals proprietary structure-based drug discovery platform technology.
  • CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains.

Global Formulation Development Outsourcing Industry Analysis, 2022-2027 - Featuring Profiles of Charles River Labs, Aizant Drug Research Solutions, Lonza Group, and Dr. Reddy's Labs Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, June 3, 2022
Health, Pharmaceutical, Green List, Research, Catalent, Pharmaceutics, US Foods, Patent, Charles River Laboratories, Orange Book, MFDS, FDA, Infection, COVID-19, Generic, Favipiravir, LabCorp, Korean Ministry of Culture, CAGR, USD, Pharmaceutical industry, Fine chemical, Food, Growth

The "Formulation Development Outsourcing Market - Growth, Size, Trends, COVID-19 Impact, and Forecasts (2022-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Formulation Development Outsourcing Market - Growth, Size, Trends, COVID-19 Impact, and Forecasts (2022-2027)" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 pandemic, countries' health systems are rapidly investing in research and development to combat the virus having a significant impact on the formulation development outsourcing market.
  • Thus, the onset of the pandemic has significantly benefitted the formulation development outsourcing market.
  • As a result of which, there has been an increase in the formulation development outsourcing activities, thereby contributing to the market growth.

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Retrieved on: 
Thursday, April 28, 2022
Mpro, Solution, Program, USAMRIID, Vaccine, CEO, Biotechnology, Percussion section, Fujifilm, Infection, Health, MD, Protease, Multimedia, Research, View, Digital imaging, United States Department of Defense, Hand, Risk, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Molnupiravir, Favipiravir

The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.

Key Points: 
  • The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.
  • Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone.
  • We are working with FUJIFILM Toyama to benefit from their decades of experience in oral antivirals."
  • For more information, please visit: holdings.fujifilm.com
    Healion Bio, Inc., Frederick, MD, is a biotechnology development company developing the next generation of antiviral compounds.

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Retrieved on: 
Thursday, April 28, 2022
Mpro, Solution, Program, USAMRIID, Vaccine, CEO, Biotechnology, Percussion section, Fujifilm, Infection, Health, MD, Protease, Research, Digital imaging, United States Department of Defense, Hand, Risk, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Molnupiravir, Favipiravir

The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.

Key Points: 
  • The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.
  • Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone.
  • We are working with FUJIFILM Toyama to benefit from their decades of experience in oral antivirals."
  • For more information, please visit: holdings.fujifilm.com
    Healion Bio, Inc., Frederick, MD, is a biotechnology development company developing the next generation of antiviral compounds.

COVID-19 Drug Associated APIs Global (Synthetic, Biotech, Captive & Merchant) Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 18, 2022
Health, General Health, Salbutamol, Joint Medical Service (Germany), Malaria, API, Favipiravir, Growth, Parenteral Drug Association, Coronavirus, Business, EUA, Laboratory, Medicine, Cisatracurium besilate, Alembic Pharmaceuticals, COVID-19, Lupin Limited, COVID, Azithromycin, Fentanyl, FDA, Patient, Fine chemical, Pharmaceutical industry

The "COVID-19 Drug Associated APIs Global Market Report 2022: By Drug, By Synthesis, By Business" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Drug Associated APIs Global Market Report 2022: By Drug, By Synthesis, By Business" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 drug-associated APIs market consists of sales of active pharmaceutical ingredients used in the manufacturing of COVID-19 drugs.
  • Global COVID-19 Drug Associated APIs Forecast Market, 2021-2026F, 2031F, $ Billion
    6.1.
  • Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Aditxt Signs Share Exchange Agreement to Acquire AiPharma

Retrieved on: 
Tuesday, December 28, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Company, Risk, Immune system, Security (finance), RSV, Severe acute respiratory syndrome coronavirus 2, United Kingdom, SEC, Degenerative disease, Autoimmunity, Forward-looking statement, Suite, Biochemistry, Clinical trial, RNA, Growth, Virology, Patient, Sale, Dengue virus, Annual report, Physician, Acquisition, Biology, COVID-19, Organ transplantation, Quality of life, Population, Inc., Virus, U.S. Securities and Exchange Commission, Acceleration, Industry, Technology, Therapy, Intention, Central nervous system, HCV, Dermatology, Health, Infection, Form, Anthrax, TSX, Failure, Safety, Solution, Allergy, Prospectus, Person, Pharmaceutical industry, Vaccine, Favipiravir, Nasdaq, Aditxt, AiPharma, ADITXT, AIPHARMA

Aditxt Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, has signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly-owned subsidiary of AiPharma Group Ltd. (AiPharma).

Key Points: 
  • Aditxt Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, has signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly-owned subsidiary of AiPharma Group Ltd. (AiPharma).
  • The share exchange agreement contemplates that the transaction would involve two steps.
  • The definitive agreement follows Aditxts prior announcement on August 25, 2021, of its intention to acquire AiPharma and Aditxts bridge loan funding to AiPharma, subject to certain closing conditions.
  • There may be additional risks that neither Aditxt nor AiPharma presently knows, or that Aditxt or AiPharma currently believe are immaterial.

Global COVID-19 Drug Associated APIs Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 9, 2021
Health, Pharmaceutical, Alembic Pharmaceuticals, Azithromycin, Dermatology, Medicine, Favipiravir, API, Joint Medical Service (Germany), EUA, Growth, Pain, Safety, Parenteral Drug Association, Salbutamol, Coronavirus, INR, Patient, COVID, Neurology, Gastroenterology, Cisatracurium besilate, COVID-19, Remdesivir, Lupin Limited, VMS, Fentanyl, FDA, Laboratory, Acquisition, Animal, Pharmaceutical industry, Fine chemical

The "COVID-19 Drug Associated APIs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Drug Associated APIs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Global COVID-19 Drug Associated APIs Historic Market, 2015-2020, $ Billion
    5.2.
  • Global COVID-19 Drug Associated APIs Forecast Market, 2020-2025F, 2030F, $ Billion
    6.1.
  • Global COVID-19 Drug Associated APIs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021

Retrieved on: 
Monday, April 19, 2021
Biotechnology, Pharmaceutical, Health, Chemistry, Physical sciences, Ebola, Chemical compounds, COVID-19, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, XC2, Antiviral drug, Infection

By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Key Points: 
  • By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan\xc2\xae / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.
  • For more information, visit www.AppiliTherapeutics.com .\nBloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.

Appili Therapeutics to Present as Part of Canada’s Top Three Pitches at Biocom’s Global Life Science Partnering Conference Today

Retrieved on: 
Wednesday, February 24, 2021
Biotechnology, Pharmaceutical, Health, Chemistry, Physical sciences, Chemical compounds, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Infection, Biocom Global, Appili Therapeutics

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.